Search

Joseph P Balint

from Seattle, WA
Age ~76
Get Report
Also known as:
Joe P Balint
Phone and address:
520 2Nd Ave W APT 311, Seattle, WA 98119
(206) 283-3779
Connected to:
Csilla Balint, 56Frances L Balint, 88Kemarie R Balint, 36Marika A Balint, 56Valeria Balint, 64Allison B Balis, 52Andrea F Balis, 76Jillian L Balis, 52Ralph M Balisalisa, 46Frank R Balisciano, 43

Joseph Balint Phones & Addresses

  • 520 2Nd Ave W APT 311, Seattle, WA 98119 (206) 283-3779
  • 520 2Nd Ave W, Seattle, WA 98119

Resumes

Resumes

Joseph Balint Photo 1

Senior Scientist

View page
Location:
Seattle, WA
Industry:
Biotechnology
Work:
Etubics
Senior Scientist
Skills:
Cell Culture
Joseph Balint Photo 2

Scientist

View page
Location:
Seattle, WA
Industry:
Biotechnology
Work:
Etubics
Scientist
Joseph Balint Photo 3

Mechanical Cad Designer At Inca Engineers

View page
Location:
Greater Seattle Area
Industry:
Machinery

Business Records

Name / Title
Company / Classification
Phones & Addresses
Joseph Balint
OHIO VALLEY TESTING LLC
Joseph Balint
Director
Etubics
Mfg Bread/Related Products
410 W Harrison St, Seattle, WA 98119

Publications

Us Patents

Sequential Administration Of A Replication Defective Adenovirus Vector In Vaccination Protocols

View page
US Patent:
8298549, Oct 30, 2012
Filed:
Jan 4, 2010
Appl. No.:
12/651836
Inventors:
Joseph P. Balint - Seattle WA, US
Frank R. Jones - Ellensburg WA, US
Assignee:
Etubics Corporation - Seattle WA
International Classification:
A61K 39/235
C12N 15/861
US Classification:
4242331, 4242051, 4353201
Abstract:
Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Sequential Administration Of A Replication Defective Adenovirus Vector In Vaccination Protocols

View page
US Patent:
20130224144, Aug 29, 2013
Filed:
Sep 18, 2012
Appl. No.:
13/622263
Inventors:
Joseph P. Balint - Seattle WA, US
Frank R. Jones - Ellensburg WA, US
Assignee:
Etubics Corporation - Seattle WA
International Classification:
A61K 39/235
A61K 38/20
A61K 38/21
A61K 38/19
US Classification:
424 851, 424 852, 424 855, 42419611, 4242051, 4242061
Abstract:
Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Method For Treatment Of Hiv-Infected Patients

View page
US Patent:
50376497, Aug 6, 1991
Filed:
Jan 24, 1989
Appl. No.:
7/301214
Inventors:
Joseph P. Balint - Seattle WA
Frank R. Jones - Edmonds WA
Assignee:
IMRE Corporation - Seattle WA
International Classification:
B01D 1508
G01N 33543
G01N 33552
US Classification:
424 858
Abstract:
Patients suffering from HIV-1 infection, including both those who have and those who have not developed acquired immunodeficiency syndrome, are treated by extracorporeal removal of IgG and immune complexes. An immunoadsorbent material for removing IgG and IgG-complexes from biological fluids is prepared by covalently binding protein A to a solid-phase silica matrix. It has been found that particularly stable, high-capacity immunoadsorbents are obtained by derivatizing the silica with amino and/or carboxyl groups, and reacting the protein A with a carbodiimide at a pH in a range from 3. 5 to 4. 5. Binding through free hydroxyl groups may be achieved with cyanogen halides at a pH in the range from 11. 0 to 11. 5. After acid washing (pH 2. 0-2. 5) to remove non-covalently bound protein A, the immunoadsorbent may be employed in a column for therapeutic treatment of various cancers and autoimmune disorders where IgG-complexes are implicated as suppressing factors in inhibiting a normal immune response.

Method For Treating Patients Suffering From Immune Thrombocytopenic Purpura

View page
US Patent:
57332541, Mar 31, 1998
Filed:
May 1, 1995
Appl. No.:
8/432036
Inventors:
Frank R. Jones - Edmonds WA
Joseph P. Balint - Seattle WA
Harry W. Snyder - Edmonds WA
Assignee:
Cypress Bioscience, Inc. - Seattle WA
International Classification:
A61M 3700
US Classification:
604 4
Abstract:
Immune thrombocytopenic purpura is treated by removal of IgG and circulating immune complexes from the patient's blood. Removal is accomplished by exposing the blood or blood plasma to an immunoadsorbent capable of removing IgG and its complexes. The immunoadsorbent comprises a suitable solid phase coupled to a receptor capable of binding IgG and its complexes, such as protein A. The IgG and its complexes are then removed by the extracorporeal exposure of the patient's blood to the immunoadsorbent, either in a continuous or discontinuous process. In the continuous process, the blood is removed in a steady flow from the patient, separated into its plasma and cellular components, the plasma treated, and the combined cellular components and treated plasma reinfused to the patient. In the discontinuous method, a small volume of blood is removed from the patient, the entire volume separated into plasma and cellular components, the plasma treated, and the entire volume of treated plasma returned to the patient, usually after the cellular components have been returned.

Anti-Human Igm Immunoadsorbent And Process For Producing Said Immunoadsorbent

View page
US Patent:
47627875, Aug 9, 1988
Filed:
Nov 21, 1986
Appl. No.:
6/934235
Inventors:
Joseph P. Balint - Seattle WA
Assignee:
IMRE Corporation - Seattle WA
International Classification:
C12N 1100
US Classification:
435174
Abstract:
An immunoadsorbent material for removing IgM and IgM-complexes from biological fluids is prepared by covalently binding anti-IgM antibodies to a solid-phase silica matrix. It has been found that reacting hydroxyl-derivatized silica in the presence of a cyanogen bromide with the anti-IgM antibodies provides a particularly stable, high-capacity immunoadsorbent. The immunoadsorbent material may be employed in a column for therapeutic treatment of various disorders, such as primary biliary cirrhosis.

Anti-Human Igm Immunoadsorbent And Process For Producing Said Immunoadsorbent

View page
US Patent:
48638692, Sep 5, 1989
Filed:
May 13, 1988
Appl. No.:
7/194669
Inventors:
Joseph P. Balint - Seattle WA
Assignee:
Imre Cororation - Seattle WA
International Classification:
C12M 124
US Classification:
435296
Abstract:
An immunoadsorbent material for removing IgM and IgM-complexes from biological fluids is prepared by covalently binding anti-IgM antibodies to a solid-phase silica matrix. It has been found that reacting hydroxy-derivatized silica in the presence of cyanogen bromide with the anti-IgM antibodies provides a particularly stable, high-capacity immunoadsorbent. The immunoadsorbent material may be employed in a column for therapeutic treatment of various disorders, such as primary biliary cirrhosis.

Methods And Compositions For Transient Elimination Of Humoral Immune Antibodies

View page
US Patent:
48658413, Sep 12, 1989
Filed:
Oct 23, 1987
Appl. No.:
7/112853
Inventors:
Joseph P. Balint - Seattle WA
Sharon Cochran - Edmonds WA
Frank R. Jones - Edmonds WA
Harry W. Snyder - Edmonds WA
Assignee:
Imre Corporation - Seattle WA
International Classification:
A61K 3900
C12N 1100
G01N 33552
US Classification:
424 858
Abstract:
Antibody is removed from the blood of patients who are being treated or diagnosed with exogenous macromolecules, such as immunotoxins. As the immunotoxins are foreign antigens, the patient will develop an immune response. The antibodies produced by the immune response upon subsequent immunization with the immunotoxins will interfere with the desired function of the immunotoxins by preventing them from binding with their specific target site. By extracorporeally removing the antibodies, the activity of the immunotoxins can be enhanced.

Method For Treatment Of Kaposi's Sarcoma

View page
US Patent:
48014494, Jan 31, 1989
Filed:
Dec 31, 1986
Appl. No.:
6/948268
Inventors:
Joseph P. Balint - Seattle WA
Frank R. Jones - Edmonds WA
Assignee:
IMRE Corporation - Seattle WA
International Classification:
G01N 33552
G01N 33543
B01D 1508
US Classification:
424 858
Abstract:
An immunoadsorbent material for removing IgG and IgG-complexes from biological fluids is prepared by covalently binding protein A to a solid-phase silica matrix. It has been found that particularly stable, high-capacity immunoadsorbents are obtained by derivatizing the silica with amino and/or carboxyl groups, and reacting the protein A with a carbodiimide at a pH in the range from 3. 5 to 4. 5. Binding through free hydroxyl groups may be achieved with cyanogen halides at a pH in the range from 11. 0 to 11. 5. After acid washing (pH 2. 0-2. 5) to remove non-covalently bound protein A, the immunoadsorbent may be employed in a column for therapeutic treatment of various cancers and autoimmune disorders where IgG-complexes are implicated as suppressing factors in inhibiting a normal immune response. The column has been successfully employed in treating patients suffering from Kaposi's sarcoma.
Control profile
Joseph P Balint from Seattle, WA, age ~76 Get Report